121 related articles for article (PubMed ID: 24258994)
21. LINE-1 hypomethylation and mutational status in cutaneous melanomas.
Pramio DT; Pennacchi PC; Maria-Engler SS; Campos AH; Duprat JP; Carraro DM; Krepischi AC
J Investig Med; 2016 Apr; 64(4):899-904. PubMed ID: 26965315
[TBL] [Abstract][Full Text] [Related]
22. A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma.
Jakub JW; Grotz TE; Jordan P; Hunter E; Pittelkow M; Ramadass A; Akoulitchev A; Markovic S
Melanoma Res; 2015 Oct; 25(5):406-11. PubMed ID: 26225582
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
Liu S; Ren S; Howell P; Fodstad O; Riker AI
Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
[TBL] [Abstract][Full Text] [Related]
24. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma.
van Elsas A; Zerp SF; van der Flier S; Krüse KM; Aarnoudse C; Hayward NK; Ruiter DJ; Schrier PI
Am J Pathol; 1996 Sep; 149(3):883-93. PubMed ID: 8780392
[TBL] [Abstract][Full Text] [Related]
25. The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma.
Bougnoux AC; Solassol J
Clin Biochem; 2013 Apr; 46(6):518-23. PubMed ID: 23262402
[TBL] [Abstract][Full Text] [Related]
26. New developments in biomarkers for melanoma.
Griewank KG; Ugurel S; Schadendorf D; Paschen A
Curr Opin Oncol; 2013 Mar; 25(2):145-51. PubMed ID: 23334230
[TBL] [Abstract][Full Text] [Related]
27. Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns.
Harbst K; Staaf J; Måsbäck A; Olsson H; Ingvar C; Vallon-Christersson J; Ringnér M; Borg A; Jönsson G
Melanoma Res; 2010 Oct; 20(5):381-91. PubMed ID: 20848731
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of serum LINE-1 hypomethylation as a prognostic marker for hepatocellular carcinoma.
Ramzy II; Omran DA; Hamad O; Shaker O; Abboud A
Arab J Gastroenterol; 2011 Sep; 12(3):139-42. PubMed ID: 22055592
[TBL] [Abstract][Full Text] [Related]
29. How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis.
Hatzimichael E; Syed N; Lo Nigro C; Rao B; Crook T
Expert Rev Mol Diagn; 2014 Jul; 14(6):639-42. PubMed ID: 24926921
[TBL] [Abstract][Full Text] [Related]
30. The laser capture microdissection cannot be replaced with the macrodissection.
Sunami E; Watanabe T
Exp Mol Pathol; 2014 Apr; 96(2):206. PubMed ID: 24480541
[No Abstract] [Full Text] [Related]
31. Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system.
Belloni B; Lambertini C; Nuciforo P; Phillips J; Bruening E; Wong S; Dummer R
J Clin Pathol; 2013 Feb; 66(2):124-35. PubMed ID: 23125305
[TBL] [Abstract][Full Text] [Related]
32. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies.
Gallagher WM; Bergin OE; Rafferty M; Kelly ZD; Nolan IM; Fox EJ; Culhane AC; McArdle L; Fraga MF; Hughes L; Currid CA; O'Mahony F; Byrne A; Murphy AA; Moss C; McDonnell S; Stallings RL; Plumb JA; Esteller M; Brown R; Dervan PA; Easty DJ
Carcinogenesis; 2005 Nov; 26(11):1856-67. PubMed ID: 15958521
[TBL] [Abstract][Full Text] [Related]
33. Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements.
Chandler WM; Rowe LR; Florell SR; Jahromi MS; Schiffman JD; South ST
Arch Pathol Lab Med; 2012 Aug; 136(8):947-55. PubMed ID: 22849744
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of sex determining region Y-box 11 (SOX11) in cutaneous malignant melanoma.
Jian J; Guoying W; Jing Z
J Int Med Res; 2013 Aug; 41(4):1221-7. PubMed ID: 23867449
[TBL] [Abstract][Full Text] [Related]
36. Association of HERV-K and LINE-1 hypomethylation with reduced disease-free survival in melanoma patients.
Cardelli M; Doorn RV; Larcher L; Donato MD; Piacenza F; Pierpaoli E; Giacconi R; Malavolta M; Rachakonda S; Gruis NA; Molven A; Andresen PA; Pjanova D; van den Oord JJ; Provinciali M; Nagore E; Kumar R
Epigenomics; 2020 Oct; 12(19):1689-1706. PubMed ID: 33125285
[No Abstract] [Full Text] [Related]
37. Is DNA ploidy of prognostic significance in stage I cutaneous melanoma?
Gattuso P; Reddy V; Solans E; Kathuria S; Aranha GV; Jacobs HK; Walloch J
Surgery; 1990 Oct; 108(4):702-8; discussion 708-9. PubMed ID: 2218882
[TBL] [Abstract][Full Text] [Related]
38. A search for CDKN2A/p16INK4a mutations in melanocytic nevi from patients with melanoma and spouse controls by use of laser-captured microdissection.
Wang H; Presland RB; Piepkorn M
Arch Dermatol; 2005 Feb; 141(2):177-80. PubMed ID: 15724013
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical diagnostic and prognostic markers for melanoma.
Nosrati M; Kashani-Sabet M
Methods Mol Biol; 2014; 1102():259-73. PubMed ID: 24258983
[TBL] [Abstract][Full Text] [Related]
40. Quantitative DNA methylation analysis of laser capture microdissected formalin-fixed and paraffin-embedded tissues.
Gagnon JF; Sanschagrin F; Jacob S; Tremblay AA; Provencher L; Robert J; Morin C; Diorio C
Exp Mol Pathol; 2010 Feb; 88(1):184-9. PubMed ID: 19818762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
